pharma

Sanofi will license Owkin's K Pro platform for five years and co-develop autonomous AI agents for drug R&D, extending a partnership that began in 2021 and made Owkin a unicorn.

OpenAI's first domain-specific model for biology and drug discovery connects to 50+ scientific databases and outperformed human experts on RNA sequence tasks, but faces established rivals and a decade-long clinical validation gap.

The Danish pharmaceutical giant will integrate OpenAI's frontier models across R&D, manufacturing, and supply chain, with full deployment targeted by year-end.

The first once-weekly treatment for achondroplasia is now commercially available in the United States after Ascendis Pharma secured orphan drug exclusivity through 2033.

Tozorakimab becomes the first IL-33-targeting biologic to show statistically significant reductions in COPD exacerbations across two confirmatory Phase 3 trials, after competitors Sanofi and Roche stumbled in the same drug class.